Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas M Sproule

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Market Access & Health Policy|March 12, 2021
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)Rebecca Dean, Ivar Jensen, Phil Cyr, et al.
Journal of Child Neurology|October 9, 2010
Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophyDouglas M Sproule, Mark Punyanitya, Wei Shen, et al.
Muscle & Nerve|July 30, 2013
The motor neuron response to SMN1 deficiency in spinal muscular atrophyPeter B Kang, Clifton L Gooch, Michael P McDermott, et al.
Neuromuscular Disorders : NMD|July 9, 2010
Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophyDouglas M Sproule, Jacqueline Montes, Sally Dunaway, et al.
Pediatric Pulmonology|December 15, 2018
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapySamiah Al-Zaidy, A Simon Pickard, Kavitha Kotha, et al.
Pediatric Neurology|July 7, 2019
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement TherapyLinda P Lowes, Lindsay N Alfano, W David Arnold, et al.
Journal of Neuromuscular Diseases|August 6, 2019
AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History CohortSamiah A Al-Zaidy, Stephen J Kolb, Linda Lowes, et al.
Nature Medicine|October 5, 2021
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissueGretchen Thomsen, Arthur H M Burghes, Caroline Hsieh, et al.
Plos One|April 9, 2013
SMA-MAP: a plasma protein panel for spinal muscular atrophyDione T Kobayashi, Jing Shi, Laurie Stephen, et al.
Neurology|August 1, 2014
Observational study of spinal muscular atrophy type I and implications for clinical trialsRichard S Finkel, Michael P McDermott, Petra Kaufmann, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Market Access & Health Policy|March 12, 2021
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)Rebecca Dean, Ivar Jensen, Phil Cyr, et al.
Journal of Child Neurology|October 9, 2010
Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophyDouglas M Sproule, Mark Punyanitya, Wei Shen, et al.
Muscle & Nerve|July 30, 2013
The motor neuron response to SMN1 deficiency in spinal muscular atrophyPeter B Kang, Clifton L Gooch, Michael P McDermott, et al.
Neuromuscular Disorders : NMD|July 9, 2010
Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophyDouglas M Sproule, Jacqueline Montes, Sally Dunaway, et al.
Pediatric Pulmonology|December 15, 2018
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapySamiah Al-Zaidy, A Simon Pickard, Kavitha Kotha, et al.
Pediatric Neurology|July 7, 2019
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement TherapyLinda P Lowes, Lindsay N Alfano, W David Arnold, et al.
Journal of Neuromuscular Diseases|August 6, 2019
AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History CohortSamiah A Al-Zaidy, Stephen J Kolb, Linda Lowes, et al.
Nature Medicine|October 5, 2021
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissueGretchen Thomsen, Arthur H M Burghes, Caroline Hsieh, et al.
Plos One|April 9, 2013
SMA-MAP: a plasma protein panel for spinal muscular atrophyDione T Kobayashi, Jing Shi, Laurie Stephen, et al.
Neurology|August 1, 2014
Observational study of spinal muscular atrophy type I and implications for clinical trialsRichard S Finkel, Michael P McDermott, Petra Kaufmann, et al.
Pageof 4